Siham Ceballos
Founder and Managing Partner Innosuisse
Seminars
Wednesday 28th January 2026
Panel Discussion: De-Risking mRNA Innovation to Attract Investment & Partnerships in a Post-Vaccine Era
4:00 pm
- What makes an mRNA therapeutic platform fundable in 2026? What clinical and strategic proof do VCs want to see?
- How are biotech leaders navigating delivery licensing limitations, high COGS, and regulatory uncertainty to stay attractive to partners?
- Are non-US trial strategies, earlier pharma engagement, or new reimbursement models the key to investor re-engagement?
